The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors

Authors :: Domenica Lorusso
Elena Garralda
Ignacio Matos
Ulrich Keilholz
Alfredo Zurlo
Josep Tabernero
Riccardo Belli
Hans Baumeister
Maxim Kebenko
Gianluca Del Conte
Luca Gianni
Konrad Klinghammer
Christina Dicke
Francesco Raspagliesi
Beate Habel
Walter Fiedler
Sebastian Ochsenreither
Source :: Journal of Clinical Oncology. 36:TPS2596-TPS2596
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: TPS2596Background: TO (CetuGEX) is a second-generation anti-EGFR antibody that specifically binds to EGFR and acts as a competitive antagonist at the ligand binding site. GAT (PankoMab-GEX) is a no...

Subjects :: Cancer Research
genetic structures
biology
business.industry
Oncology
Competitive antagonist
Phase (matter)
Cancer research
biology.protein
Medicine
In patient
Antibody
business
MUC1

Tools